[
  {
    "ts": null,
    "headline": "Incyte (INCY): Evaluating Valuation as Baricitinib Advances Toward Expanded Approval for Adolescent Alopecia Areata",
    "summary": "New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results. See our latest analysis for Incyte. Incyte’s momentum has really picked up this year thanks to positive trial results and recent pipeline updates, such as its advances in atopic dermatitis and cancer immunotherapies. The stock’s strong 31% share price...",
    "url": "https://finnhub.io/api/news?id=4ddc785d716799a213a367042dd19d521b9065fe6415776bfb882123be484b0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761501990,
      "headline": "Incyte (INCY): Evaluating Valuation as Baricitinib Advances Toward Expanded Approval for Adolescent Alopecia Areata",
      "id": 137215914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals for expanded use based on these results. See our latest analysis for Incyte. Incyte’s momentum has really picked up this year thanks to positive trial results and recent pipeline updates, such as its advances in atopic dermatitis and cancer immunotherapies. The stock’s strong 31% share price...",
      "url": "https://finnhub.io/api/news?id=4ddc785d716799a213a367042dd19d521b9065fe6415776bfb882123be484b0e"
    }
  },
  {
    "ts": null,
    "headline": "3 Biopharma Names I Am Buying After Avadel's Buyout",
    "summary": "Biotech and biopharma M&A activity has surged in recent weeks, sparking a strong sector rally and renewed optimism. Learn why stocks like AVDL look attractive.",
    "url": "https://finnhub.io/api/news?id=1d9301a3ffaa172ac5a40b83c53110018cc8b099567bb3642091b92f39e889f2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761471935,
      "headline": "3 Biopharma Names I Am Buying After Avadel's Buyout",
      "id": 137212208,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Biotech and biopharma M&A activity has surged in recent weeks, sparking a strong sector rally and renewed optimism. Learn why stocks like AVDL look attractive.",
      "url": "https://finnhub.io/api/news?id=1d9301a3ffaa172ac5a40b83c53110018cc8b099567bb3642091b92f39e889f2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Is Another Monster Quarter Coming",
    "summary": "Discover why Eli Lillyâs Q3 results and Adverum acquisition boost its risk/reward profile.",
    "url": "https://finnhub.io/api/news?id=7b335fd199e2e11bf7a03b65a5dae893b468b8b610800c92c23b6a88cf3faf8f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761466500,
      "headline": "Eli Lilly: Is Another Monster Quarter Coming",
      "id": 137211818,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202955977/image_1202955977.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Eli Lillyâs Q3 results and Adverum acquisition boost its risk/reward profile.",
      "url": "https://finnhub.io/api/news?id=7b335fd199e2e11bf7a03b65a5dae893b468b8b610800c92c23b6a88cf3faf8f"
    }
  },
  {
    "ts": null,
    "headline": "Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth",
    "summary": "Madrigal Pharmaceuticals sees rapid Rezdiffra sales growth with EU approval and long-term GLP-1 strategy. Learn why MDGL stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=856981acdfc86c4654ebfb1a2905edae7600aa34be5e1050df4f1fcdce649c2a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761462305,
      "headline": "Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth",
      "id": 137211526,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2204862925/image_2204862925.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Madrigal Pharmaceuticals sees rapid Rezdiffra sales growth with EU approval and long-term GLP-1 strategy. Learn why MDGL stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=856981acdfc86c4654ebfb1a2905edae7600aa34be5e1050df4f1fcdce649c2a"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Week Ahead",
    "summary": "Get the latest stock market updates, Q3 earnings highlights, and expert gold investment insights.",
    "url": "https://finnhub.io/api/news?id=c68aad4ae2924996a3a5d51f7fb2a98117fe57727304ada2cbac36ac95e0a414",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761462095,
      "headline": "Wall Street Week Ahead",
      "id": 137211528,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156176139/image_2156176139.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Get the latest stock market updates, Q3 earnings highlights, and expert gold investment insights.",
      "url": "https://finnhub.io/api/news?id=c68aad4ae2924996a3a5d51f7fb2a98117fe57727304ada2cbac36ac95e0a414"
    }
  }
]